PCDHGB7 hypermethylation-based Cervical cancer Methylation (CerMe) detection for the triage of high-risk human papillomavirus-positive women: a prospective cohort study

• DOI: 10.1186/s12916-024-03267-5
• Publication Date: 2024-02-05T13:02:28Z
• Authors: Dan Cao; Zhicong Yang; Shihua Dong; Yuhong Li; Zhanrui Mao; Qi Lu; Peng Xu; Minfang Shao; Lei Pan; Xu Han; Jiangjing Yuan; Qiong Fan; Lei Chen; Yanzhong Wang; Weipei Zhu; Wenqiang Yu; Yudong Wang
• Keywords: Triage; Cervical screening

Abstract Background Implementation of high-risk human papillomavirus (hrHPV) screening has greatly reduced the incidence and mortality cervical cancer. However, a triage strategy that is effective, noninvasive, independent from subjective interpretation pathologists urgently required to decrease unnecessary colposcopy referrals in hrHPV-positive women. Methods A total 3251 women aged 30–82 years (median = 41 years) International Peace Maternity Child Health Hospital were included training set ( n 2116) validation 1135) establish Cervical cancer Methylation (CerMe) detection. The performance CerMe as for was evaluated. Results detection efficiently distinguished intraepithelial neoplasia grade 2 or worse (CIN2 +) 1 normal (CIN1 −) with excellent sensitivity 82.4% (95% CI 72.6 ~ 89.8%) specificity 91.1% 89.2 92.7%). Importantly, showed improved (92.1% vs. 74.9%) other 12 hrHPV type-positive well superior (80.8% 61.5%) (88.9% 75.3%) HPV16/18 compared cytology testing. performed ASC-US (sensitivity 74.4%, 87.5%) LSIL 84.4%, 83.9%). Conclusions PCDHGB7 hypermethylation-based can be used reduce over-referrals. Trial registration ChiCTR2100048972. Registered on 19 July 2021.